555 Mission Street, Suite 3000 , San Francisco, CA 94105-0921 USA
Ryan Murr is a partner in the San Francisco office of Gibson, Dunn & Crutcher, where he serves as a member of the firm’s Corporate Transactions Department, with a practice focused on representing leading companies, investors and underwriters in the life sciences and technology space. Mr. Murr currently serves as a Co-Chair of the firm’s Life Sciences Practice Group and as a member of the firm-wide Executive Committee.
Mr. Murr represents public and private companies, investors and underwriters in the biotechnology, pharmaceutical, technology and medical device industries in connection with securities offerings and business combination transactions. In addition, Mr. Murr regularly serves as principal outside counsel for publicly traded companies and private venture-backed companies, advising management teams and boards of directors on corporate law matters, SEC reporting, corporate governance, licensing transactions, and mergers & acquisitions.
Recognized by Chambers USA in the area of Life Sciences, clients describe Mr. Murr as “creative and smart” and someone who “gets the better of the other side.”
Legal Media Group (Euromoney) has ranked Mr. Murr nationally as a “Star” in Life Sciences in the areas of Corporate, Licensing & Collaboration, Mergers & Acquisitions and Venture Capital. Mr. Murr has twice been nominated by Legal Media Group as “Finance & Transactional Attorney of the Year.”
Mr. Murr has served as a member of the American Bar Association’s Mergers and Acquisitions Subcommittee, is a member of the San Francisco Bar Association, and is active in advising various not-for-profit entities in the San Francisco Bay Area.
Prior to joining Gibson Dunn, Mr. Murr served as the Office Managing Partner for the San Francisco office of Ropes & Gray, LLP.
Mr. Murr has represented issuers in a range of capital markets transactions, including initial public offerings, private placements (ranging from early-stage investments to crossover rounds and PIPEs), follow-on equity financings and debt financings.
Notable financing transactions include representing a private equity-backed biotechnology company in its $160 million initial public offering in 2017, which was one of the ten largest IPOs in California in that year. In 2018, Mr. Murr represented a global private equity fund as the lead investor in a $300 million Series A investment in connection with a carve-out acquisition from a large pharmaceutical company. Mr. Murr has deep experience with a range of financing transaction structures beyond traditional underwritten offerings, including at-the-market offerings, PIPEs, and equity lines.
Mr. Murr regularly represents investors in the life sciences and technology space, including private equity funds, hedge funds, and venture capital funds. Financing transactions have included public and private offerings ranging from passive investments to bespoke control structures and spin-outs.
Mr. Murr has also represented underwriters in numerous capital market transactions, including initial public offerings and follow-on equity offerings.
Mr. Murr regularly advises pharmaceutical, biotechnology, technology, and medical device companies in connection with significant strategic transactions, including: tender offers, public and private mergers, stock and asset purchases, and licensing transactions. Noteworthy engagements have included:
Mr. Murr has also advised investment funds, biopharmaceutical companies and academic institutions in connection with royalty monetization transactions, including the purchase and sale of future royalty streams and financing transactions involving synthetic royalties.
University of San Diego - 1998 Juris Doctor
University of San Diego - 1998 Master of Arts
University of Oregon - 1993 Bachelor of Arts